Drug Database
PO

poliomyelitis vaccine (inactivated) (Poliorix)

✓ Approved

GSK · Vaccine · Vaccine

What is poliomyelitis vaccine (inactivated)?

poliomyelitis vaccine (inactivated) is a vaccine developed by GSK. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesPoliorix
CompanyGSK
Drug ClassVaccine, Large Molecules
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, GSK

Therapeutic Indications

poliomyelitis vaccine (inactivated) is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Surgical and medical proceduresPolio immunisation✓ Approved

Related Research Articles

PubMedAAPS PharmSciTech2026-09-19

Comprehensive Stability Assessment of Squalene in a Nanoemulsion Adjuvant and the SpiN-Tec Vaccine: HPLC Quantification, Stress Testing, and Stability Studies.

Gomes Isabela Pereira IP, Rivelli Graziella Gomes GG, Bagno Flávia Fonseca FF, Hojo-Souza Natália Satchiko NS et al.

Squalene-based nanoemulsions are widely used as adjuvants in vaccine formulations, but their stability can be affected by environmental factors such as pH, oxidative stress, temperature, and light. We have produced a squalene nanoemulsion (CTVad1) to support the clinical development of new vaccines. This study aimed to develop and validate an HPLC method for squalene quantification in SpiN-Tec, a recombinant protein vaccine against COVID-19. We also aimed to evaluate the stability of the CTVad1 adjuvant and SpiN-Tec under controlled storage conditions. A reversed-phase HPLC method was developed and validated, and comprehensive forced degradation studies were performed on the raw material and SpiN-Tec under acidic, basic, oxidative, thermal, and photolytic conditions to demonstrate the stability-indicating capability of the method. Physicochemical, morphological, and biological characteristics were assessed, and stability studies of both the vaccine and the CTVad1 adjuvant were performed under accelerated and long-term conditions. The HPLC method was selective, precise, accurate, linear, and robust. Squalene raw material degraded under all tested conditions, whereas formulation in nano-sized globules improved its stability, with degradation observed only under hydrogen peroxide and light exposure. CTVad1 remained stable over time, exhibiting only minor, non-critical changes within the specification limits in both accelerated and long-term stability studies, regardless of the glass packaging used (clear or amber). In addition, the SpiN-Tec vaccine maintained its physicochemical and biological integrity under all tested conditions, with all evaluated parameters remaining within the established specification ranges. Our findings demonstrate that proper formulation, packaging, and storage conditions can preserve squalene stability in nanoemulsion-based vaccines, ensuring the quality, safety, and efficacy of the SpiN-Tec vaccine and its adjuvant throughout shelf life.

PMID 42760453
Read full article →
PubMedOcular immunology and inflammation2026-09-19

Bilateral Maculopathy in an Infant Following Measles, Mumps, Rubella, and Varicella-Zoster (MMRV) Vaccination.

Ben-Avi Ravid R, Amer Radgonde R

To report on the long-term clinical outcome of a healthy infant who presented with posterior uveitis following the administration of the combined measles, mumps, rubella, and varicella (MMRV) vaccine. Descriptive case report. A 13-month-old infant presented with bilateral visual loss two weeks after receiving the MMRV vaccine. Ophthalmic examination revealed bilateral retinitis and retinal vasculitis with exudative retinal detachment. Extensive infectious work-up was conducted including serologic exams and PCR testing of blood, aqueous humor, cerebrospinal fluid and urine. Serological tests for measles yielded positive IgM and IgG titers. PCR testing for measles in the aqueous humor and urine was negative. Neurologic assessment and neuroimaging were unremarkable, excluding central nervous system involvement. Empiric systemic antiviral and corticosteroid therapy was initiated. Gradual resolution of posterior uveitis ensued, culminating in bilateral macular scars. Over a six-year follow-up period, the patient demonstrated stable ocular findings with no evidence of recurrent inflammation or systemic autoimmune disease. Final visual acuity was 6/9 in each eye. This case represents a rare occurrence of non-necrotizing retinitis following MMRV vaccination. To our knowledge, this is the first report describing the sequential OCT characteristics of presumed measles vaccine-associated retinitis. The prolonged follow-up period supports the absence of an alternative etiology and provides valuable insight into the long-term course and visual prognosis of vaccine-associated retinopathy.

PMID 42760840
Read full article →
PubMedPhotochemistry and photobiology2026-09-19

Dual-photosensitizer polylactic acid filaments for 3D-printed photodynamic antimicrobial materials.

Gómez Jesús J, Fleming Michael M, Paudyal Nitika N, Khan Taufiq T et al.

3D-printed photodynamic materials offer a route to fabricate light-activated antimicrobial objects, but their performance depends strongly on photosensitizer (PS) retention, accessibility, and photophysical behavior after thermal processing. Here, rose bengal (RB) and zinc(II) phthalocyanine (ZnPc) were incorporated into polylactic acid (PLA) at 0.5% (w/w) and processed by melt extrusion and three-dimensional printing. The characteristic absorption and fluorescence emission bands of both chromophores were retained after processing, and the dual formulation provided complementary absorption in the green and red regions of the visible spectrum. RB release from the dual-PS material followed biexponential kinetics, with kfast = 1.39 ± 0.29 min-1 and kslow = 0.013 ± 0.004 min-1. Under white-light irradiation, RB-containing materials produced approximately 5-6 log reductions (>99.999%) in bacterial viability, with Bacillus subtilis inactivated more rapidly than Escherichia coli. ZnPc-containing PLA alone produced only partial inactivation, and no appreciable dark toxicity was observed. These results identify PS accessibility as a critical parameter governing the performance of melt-processed photodynamic materials.

PMID 42760816
Read full article →
PubMedMedScience2026-09-19

Neoantigen cancer vaccines for gastrointestinal tumors: opportunities and challenges.

Zhao Zixuan Z, Du Xinyu X, Gao Xiaoliang X, Zhao Sheng S et al.

Gastrointestinal tumors are characterized by high global incidence and mortality rates. Although immune checkpoint inhibitors (ICIs) have achieved breakthroughs in some of these cancers, their overall response rate remains low. Neoantigen cancer vaccines have emerged as a promising new strategy for immunotherapy in gastrointestinal tumors due to their high specificity and strong immunogenicity. These vaccines effectively activate specific T-cell immunity and can produce synergistic effects when combined with ICIs. Various vaccine platforms offer distinct advantages, and clinical trials have shown encouraging potential in inducing immune responses and extending progression-free survival. Meanwhile, current challenges and future directions cannot be ignored. Key challenges primarily involve the accuracy of neoantigen prediction, tumor heterogeneity, and optimal treatment timing. Future directions include artificial intelligence (AI)-assisted multi-omics screening, the development of universal vaccines, optimization of novel delivery systems, and multimodal combination strategies. These advances are expected to promote the application of neoantigen cancer vaccines in postoperative recurrence prevention and early-stage treatment, ultimately moving toward personalized precision immunotherapy. This article systematically reviews the clinical progress and prospects of neoantigen cancer vaccines in treating gastrointestinal tumors, aiming to provide insights for immunotherapy in this field and offer new perspectives for further optimization of such vaccines.

PMID 42760419
Read full article →
PubMedFrontiers in public health2026-09-18

Safety of Sabin-derived inactivated poliovirus vaccine in adult booster recipients: a systematic review and meta-analysis.

Hussain Muhammad M, Hassan Muhammad M, Hannan Abdul A, Kamil Arham A et al.

Poliomyelitis remains a public health concern in select regions. Sabin strain-derived inactivated poliovirus vaccine (sIPV) offers a potentially safer and cost-effective alternative to conventional IPV (cIPV) for adult booster immunization. To systematically review and meta-analyze evidence on the safety of sIPV in adults. We searched PubMed, Embase, Cochrane, and Scopus through January 2026 for randomized controlled trials comparing sIPV with cIPV/w-IPV or placebo in adults. Safety outcomes included local and systemic adverse events: pain, erythema, induration, fever, headache, malaise, and allergic reactions. Data extraction and risk of bias assessment were independently performed. Meta-analysis was conducted using random-effects models in RevMan 5.4, reporting risk ratios (RR) with 95% confidence intervals (CI). Evidence certainty was assessed using GRADE. Four trials encompassing 70-340 adults were included. Pooled analyses demonstrated no statistically significant differences in any adverse events between sIPV and cIPV: pain (RR 1.57, 95% CI 0.98-2.50), erythema (RR 1.54, 95% CI 0.64-3.69), induration (RR 0.33, 95% CI 0.04-3.06), fever (RR 0.96, 95% CI 0.39-2.33), headache (RR 0.70, 95% CI 0.21-2.37), and malaise (RR 0.75, 95% CI 0.17-3.27). Heterogeneity was negligible (I 2 = 0%). Overall, adverse events were mild, transient, and comparable across vaccines and most included trials reported no serious adverse events (SAEs), indicating a favorable safety profile. Certainty of evidence was low to very low due to small sample sizes and imprecision. sIPV demonstrates a safety profile comparable to conventional IPV in adult booster recipients, supporting its use as a viable alternative in polio eradication strategies. Further large-scale and long-term studies are warranted to confirm these findings. identifier: CRD420261329648.

PMID 42755970
Read full article →
PubMedMediterranean journal of rheumatology2026-09-18

Vaccines for Autoimmune Diseases: Stopping Triggers, Restoring BalanceA Systematic Review with Qualitative Synthesis.

de Carvalho Jozélio Freire JF, Caldas Cezar Augusto Muniz CAM, Shoenfeld Yehuda Y

To critically review the scientific background on vaccines designed to prevent autoimmune diseases, including two main strategies: (1) vaccines directed against pathogens involved in triggering disease, including Epstein-Barr virus (EBV), enterovirus and Streptococcus pyogenes; and (2) tolerogenic vaccine approaches targeting the immune response to restore tolerance to self-antigens. We performed a thorough systematic review of clinical trials, observational studies, meta-analysis and pre-clinical data. A broad search was implemented in biomedical databases and gray literature. This systematic review was conducted with qualitative synthesis, given the heterogeneity of study designs, diseases, and outcomes. Two reviewers independently selected studies for inclusion and extracted data, using standard risk of bias and quality of evidence assessment tools. There were 68 studies, 36 in humans and 32 preclinical studies included. In the anti-infective area, options include gp350 vaccine for EBV (phase 2), mRNA based early-stage vaccines, a population-based study of the impact of rotavirus vaccination on type 1 diabetes incidence, and inactivated PRV-101 Coxsackie B strain vaccine; for rheumatic fever, phase 1 trials are providing evidence with vaccines such as StreptAnova and J8/S2. With regard to the tolerogenic line, tolerogenic DC-based and of myelin peptides vaccines have shown immune regulation in illnesses such as MS and RA, but do not yet demonstrate solid clinical evidence. Trigger infections vaccines are now nearing clinical use whereas tolerogenic vaccines constitute an attractive approach for the future. The combination of these approaches has the potential to inform future preventive and therapeutic strategies, but current evidence remains heterogeneous and largely early-stage, particularly for tolerogenic platforms.

PMID 42756697
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about poliomyelitis vaccine (inactivated)